Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEco Animal Regulatory News (EAH)

Share Price Information for Eco Animal (EAH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 85.50
Bid: 83.00
Ask: 88.00
Change: 0.00 (0.00%)
Spread: 5.00 (6.024%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 85.50
EAH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

European Marketing Authorisation Opinion

22 May 2020 07:00

RNS Number : 6812N
Eco Animal Health Group PLC
22 May 2020
 

 

 22 May 2020

ECO Animal Health Group plc

(the "Group")

(AIM: EAH)

 

EUROPEAN POSITIVE OPINION FOR AIVLOSIN® IN PIGS

ECO Animal Health Group plc (the "Group") is pleased to announce that its subsidiary ECO Animal Health Limited (ECO) has received a positive opinion from the European Medicines Agency (EMA) for the use of Aivlosin® 625 mg/g Water Soluble Granules (WSG) for the treatment and metaphylaxis (disease control) of Mycoplasma hyopneumoniae in pigs.

Mycoplasma hyopneumoniae is the most common primary pathogen in pig respiratory disease and is a key instigator of secondary bacterial and viral pathogens.

Aivlosin®, ECO's patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.

The European Commission is expected to issue a marketing authorisation within two months of the publication of a positive opinion.

Marc Loomes, CEO, commented: "Aivlosin® offers a safe and highly effective medication for Mycoplasma infections. This positive opinion is significant, not only in the EU which has fifteen per cent of the world's pigs but for other large international swine markets as this indication is rolled out. Whilst we bring forward our new product development programme, particularly around vaccines, it is important to note that Aivlosin® 's approved usage continues to expand across multiple treatment areas and markets."

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

Contacts: 

ECO Animal Health Group plc

Marc Loomes (CEO)

Christopher Wilks (CFO)

020 8447 8899

IFC Advisory

Graham Herring

Zach Cohen

020 3934 6630

N+1 Singer (Nominated Adviser & Joint Broker)

Mark Taylor

Peter Steel

Alex Bond

020 7496 3000

Peel Hunt LLP (Joint Broker)

James Steel

Dr Christopher Golden

020 7418 8900

 

ECO Animal Health Group plc ("ECO" or "the "GROUP") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCABMFTMTJTBMM
Date   Source Headline
22nd Mar 20247:00 amRNSShare Awards to Executive Directors
21st Mar 20249:13 amRNSReplacement: Trading Update
21st Mar 20247:00 amRNSTrading Update
19th Mar 20249:40 amRNSGeneral Meeting Result
27th Feb 20247:00 amRNSPublication of Notice of General Meeting
6th Feb 20247:00 amRNSTrademark Approval for ECOVAXXIN® family in the EU
8th Jan 20247:00 amRNSDisposal of Freehold Properties
5th Jan 20245:05 pmRNSHolding(s) in Company
5th Jan 20245:00 pmRNSHolding(s) in Company
22nd Dec 20237:00 amRNSDeferred Option Awards to Executive Directors
1st Dec 20237:00 amRNSDirector/PDMR Shareholding
27th Nov 202310:00 amRNSInvestor Presentation
27th Nov 20237:00 amRNSResults for the six months ended 30 September 2023
14th Nov 20233:00 pmRNSHolding(s) in Company
9th Nov 20237:00 amRNSCapital Markets Day Events
24th Oct 20237:00 amRNSNew USA and Canada label claim for Aivlosin®
28th Sep 20237:00 amRNSESG Rating
7th Sep 20232:57 pmRNSResult of AGM
10th Aug 20237:00 amRNSNotice of AGM
21st Jul 20234:25 pmRNSPosting of the Annual Report and Accounts
10th Jul 20237:00 amRNSFinal Results for the Year Ended 31 March 2023
5th Jul 20237:00 amRNSNotice of Results & Investor Presentation
6th Jun 20237:00 amRNSIssue of Equity and Total Voting Rights
18th May 20237:00 amRNSHolding(s) in Company
23rd Mar 20237:00 amRNSTrading Update
8th Mar 20237:00 amRNSAnimal Health Innovation Summit
27th Feb 202310:37 amRNSDirector/PDMR Shareholding
24th Feb 20233:19 pmRNSChange of Registered Address
17th Feb 20231:41 pmRNSHolding(s) in Company
13th Feb 20231:55 pmRNSHolding(s) in Company
9th Feb 20237:00 amRNSHolding(s) in Company
9th Feb 20237:00 amRNSHolding(s) in Company
8th Feb 20237:00 amRNSDirector/PDMR Shareholding
20th Jan 202312:14 pmRNSHolding(s) in Company
13th Dec 20223:50 pmRNSDeferred Share Option Awards
30th Nov 20223:01 pmRNSDirector/PDMR Shareholding
25th Nov 20221:37 pmRNSDirector/PDMR Shareholding
23rd Nov 20227:00 amRNSResults for the six months ended 30 September 2022
22nd Nov 20227:00 amRNSInvestor Presentation covering Interim Results
14th Nov 20227:00 amRNSChange of Auditor
31st Oct 20227:00 amRNSBlock listing Interim Review
24th Oct 20221:30 pmRNSHolding(s) in Company
24th Oct 20221:28 pmRNSHolding(s) in Company
26th Sep 20224:01 pmRNSResult of AGM
5th Sep 20221:00 pmRNSInvestor Presentation covering Full Year Results
2nd Sep 20227:00 amRNSPublication of Annual Report and Notice of AGM
31st Aug 20227:00 amRNSFinal Results for the Year Ended 31 March 2022
26th Aug 20221:13 pmRNSHolding(s) in Company
25th Aug 20227:00 amRNSHolding(s) in Company
22nd Aug 20227:00 amRNSRevised Notice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.